Overview

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of three dose levels of SPI-1005 compared to placebo on vertigo, tinnitus and sensorineural hearing loss in 40 adults with Meniere's disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sound Pharmaceuticals, Incorporated
Treatments:
Ebselen